muraglitazar has been researched along with msdc-0160 in 1 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (msdc-0160) | Trials (msdc-0160) | Recent Studies (post-2010) (msdc-0160) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 9 | 2 | 8 |
| Protein | Taxonomy | muraglitazar (IC50) | msdc-0160 (IC50) |
|---|---|---|---|
| Mitochondrial pyruvate carrier 2 | Homo sapiens (human) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB | 1 |
1 other study(ies) available for muraglitazar and msdc-0160
| Article | Year |
|---|---|
PPARĪ³-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2018 |